Frontage Laboratories

Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer’s Drug, Lecanemab

EXTON, PA — Frontage’s Bioanalytical team partnered with Eisai/Biogen to support the PK and PD biomarker bioanalysis of lecanemab (BAN2401) in their investigational global phase 3 study in US and China.

Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer’s Drug, Lecanemab Read More

Frontage Laboratories

Frontage Central Labs is Awarded the Prestigious CAP Accreditation from the College of American Pathologists

EXTON, PA — Frontage Holdings Corporation announced that Frontage Central Labs has been awarded accreditation from the College of American Pathologists (CAP) after a recent on-site inspection by CAP’s Accreditation …

Frontage Central Labs is Awarded the Prestigious CAP Accreditation from the College of American Pathologists Read More